The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Regulatory News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further Regarding General Meeting

2 Sep 2014 07:00

RNS Number : 5692Q
Plethora Solutions Holdings PLC
02 September 2014
 



 

 

2 September 2014

 

Plethora Solutions Holdings PLC

("Plethora" or the "Company")

 

Further Regarding General Meeting

 

 

Further to the announcement made on 29 August 2014, Plethora Solutions Holdings plc (AIM: PLE) announces that the Company has posted a new Notice of General Meeting to Shareholders, which is intended to be in substitution for that attached to the Circular letter dated 29 August 2014. The new Notice of General Meeting to Shareholders will be made available on the Company's website, www.plethorasolutions.co.uk.

 

Shareholders are advised to disregard the Notice of General Meeting, and accompanying proxy card, attached to the Circular Letter dated 29 August 2014. It is the intention of the Board that a resolution will be put to the meeting of shareholders already scheduled for 17 September 2014 pursuant to the notice dated 29 August 2014 resolving that the meeting will be adjourned sine die. Please note that the date of the replacement General Meeting has changed to 18 September 2014.

 

Shareholders will receive a new Notice of General Meeting and a replacement Form of Proxy for use at the replacement General Meeting to be held on 18 September 2014.

 

All terms defined in that letter dated Friday, 29 August 2014 have the same meaning when used in this announcement. Shareholders and investors should read the whole text of this announcement.

 

 

Background

 

The Chairman of the Company wrote to Shareholders on Friday, 29 August 2014 in order, inter alia, to convene a General Meeting of shareholders to pass the necessary shareholders resolutions to approve the matters referred to in that Circular letter.

 

Unfortunately, the Notice of General Meeting attached to that Circular letter contained some minor printing errors. Because the Notice of General Meeting is a formal document, it is necessary to issue a new Notice of General Meeting intended to be in substitution for that attached to the Circular letter dated 29 August 2014.

 

Accordingly, a new Notice of General Meeting in which the printing errors have been corrected together with a replacement proxy card for use in relation to the Notice of General Meeting has been sent to Shareholders.

 

Shareholders are advised to disregard the Notice of General Meeting, and accompanying proxy card, attached to the Circular Letter dated 29 August 2014. It is the intention of the Board that a resolution will be put to the meeting of shareholders already scheduled for 17 September 2014 pursuant to the notice dated 29 August 2014 resolving that the meeting will be adjourned sine die.

 

Please note that the date of the replacement General Meeting has changed to 18 September 2014.

 

 

Action to be Taken

 

Shareholders will receive a new Notice of General Meeting and a replacement Form of Proxy for use at the replacement General Meeting. Whether or not Shareholders intend to attend the replacement General Meeting Shareholders are requested to complete the replacement Form of Proxy in accordance with the instructions printed on it and to return it to the Company's registrars, Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, as soon as possible, and in any event so as to arrive no later than 10:00am on 16 September 2014.

 

If Shareholders hold their Ordinary Shares in CREST they may appoint a proxy using the CREST proxy appointment service by following the instructions in note (6) to the replacement Notice of General Meeting. The completion and return of a Form of Proxy, or the electronic appointment of a proxy will not preclude Shareholders from attending the General Meeting and voting in person should they so wish.

 

 

Recommendation

 

The Directors believe that the Placing & Subscription, and therefore the Resolutions set out in the replacement Notice of General Meeting, are in the best interests of the Company and Shareholders taken as a whole. The Directors unanimously recommend that Shareholders vote in favour of those Resolutions, as they intend to do in respect of their own shareholdings, which in aggregate total 131,949,742 Ordinary Shares representing approximately 31.8% of the existing issued ordinary share capital of the Company.

 

-Ends-

 

Enquiries:

Plethora Solutions

Jim Mellon, Chairman

Jamie Gibson, CEO

Mike Wyllie, CSO

Mike Collis, CFO

Greg Bailey, NXD

 

Tel : +44(0) 20 3077 5400

Daniel Stewart (Nomad & Joint Broker)

Emma Earl / Alex Brearley (Nomad)

Martin Lampshire (Broker)

 

Tel : +44(0) 20 7776 6550

 

Hybridan LLP (Joint Broker)

Claire Louise Noyce

William Lynne

Niall Pearson

 

Tel: +44(0) 20 3713 4581

Tel: +44(0) 20 3713 4582

Tel: +44(0) 20 3713 4583

 

Britton Financial PR

Tim Blackstone

Tel: + 44 (0) 20 7242 9786

+44 (0) 7957 140416

 

About Plethora:

 

Plethora is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk

Plethora is focussed on seeking to launch PSD502™ for the treatment of premature ejaculation.

 

About PSD502™ & Premature Ejaculation:

 

PSD502™ is a topical spray for the treatment of premature ejaculation containing lidocaine and prilocaine in a eutectic-like mixture. Premature ejaculation is possibly the most common form of sexual dysfunction in men. Epidemiological studies conducted in the US and in Europe indicate a prevalence of 20 - 30% in men of all ages. There is currently no globally approved and effective pharmaceutical treatment for this condition.

 

In the absence of any widely approved pharmaceutical therapy with good patient acceptance, the premature ejaculation market offers significant potential for development and growth. An effective drug therapy for premature ejaculation may have a comparable commercial potential to the erectile dysfunction drugs.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FURUAOURSVAKRUR
Date   Source Headline
30th Sep 20087:00 amRNSInterim Results
30th Sep 20087:00 amRNSClinical Update - PSD502
11th Aug 20087:00 amRNSBoard Change
21st Jul 20082:20 pmRNSHolding(s) in Company
1st Jul 20087:05 amRNSDirector/PDMR Shareholding
1st Jul 20087:00 amRNSChange of Adviser
27th Jun 20087:00 amRNSBoard Change
23rd Jun 20082:44 pmRNSAGM Statement
19th Jun 20087:00 amRNSClinical Update PSD502 Phase
22nd May 200810:00 amRNSAnnual Report and Accounts
29th Apr 20087:00 amRNSFinal Results
24th Apr 20087:00 amRNSClinical Update - PSD508
21st Apr 200811:13 amRNSNotice of Results
1st Apr 20087:01 amRNSRe $28m Financing
10th Mar 20085:49 pmRNSHolding(s) in Company
5th Feb 20087:00 amRNSClinical Update - PSD506
10th Jan 200810:39 amRNSChange of Registered Office
19th Dec 20077:01 amRNSClinical Update - PSD502
6th Dec 20077:00 amRNSClinical Update - PSD508
29th Nov 20077:01 amRNSClinical Update PSD503
30th Oct 200712:30 pmBUSSciele Pharma and Plethora Solutions Holdings PLC Announce Initiation of Pivotal Phase III Trials for PSD502 for Premature Ejaculation
30th Oct 20077:01 amRNSClinical Update PSD502 Ph III
8th Oct 20077:00 amRNSClinical Update PSD597
26th Sep 20077:02 amRNSInterim Results
25th Sep 20074:55 pmRNSHolding(s) in Company
10th Sep 20079:27 amRNSNotice of Results
6th Sep 20077:01 amRNSClinical Update PSD597
16th Aug 20072:44 pmRNSAIM Rule 26
12th Jul 20077:01 amRNSClinical Update - PSD502
10th Jul 20074:11 pmRNSResult of AGM
2nd Jul 20073:14 pmRNSDirector/PDMR Shareholding
2nd Jul 20077:01 amRNSProduct Update - Invicorp
29th Jun 20071:20 pmRNSTotal Voting Rights
29th Jun 200710:29 amRNSShare Options Award
25th Jun 20077:01 amRNSClinical Update PSD597 for IC
14th Jun 20074:46 pmRNSHolding(s) in Company
14th Jun 20074:39 pmRNSHolding(s) in Company
1st Jun 200710:00 amRNSDirectorate Change
30th May 20077:01 amRNSPreliminary Results
24th May 20071:00 pmBUSSciele Enters Into Exclusive License Agreement with Plethora Solutions Limited to Market PSD502 for the Treatment of Premature Ejaculation
24th May 20077:05 amRNSNotice of Results
24th May 20077:03 amRNSLicensing deal
8th May 20077:02 amRNSProduct Acquisitions
5th Apr 20077:36 amRNSAcquisition
21st Mar 20075:05 pmRNSHolding(s) in Company
21st Mar 20075:05 pmRNSHolding(s) in Company
21st Mar 20075:04 pmRNSHolding(s) in Company
13th Mar 20071:08 pmRNSHolding(s) in Company
12th Mar 20072:16 pmRNSExercise of share options
1st Mar 20077:03 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.